Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ping An Biomedical CoPASW -5.90%17 Cash-to-Debt is 0.11 as of Sep. 2025, which is 1000% above its 10-year median of 0.01. GuruFocus rates PASW with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 1,011 Manufacturing - Apparel & Accessories companies, Ping An Biomedical Co ranks worse than 75.57% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Ping An Biomedical Co's cash to debt ratio for the quarter that ended in Sep. 2025 was 0.11.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Ping An Biomedical Cocouldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2025.
The historical rank and industry rank for Ping An Biomedical Co's Cash-to-Debt or its related term are showing as below:
PASW'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.11
Current: 0.11
During the past 5 years, Ping An Biomedical Co's highest Cash to Debt Ratio was 0.11. The lowest was 0.00. And the median was 0.01.
Ping An Biomedical Co (NAS:PASW) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Ping An Biomedical Co Cash-to-Debt Related Terms
Ping An Biomedical Co Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Ping An Biomedical Co's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Textile Manufacturing subindustry, Ping An Biomedical Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ping An Biomedical Co Cash-to-Debt vs Manufacturing - Apparel & Accessories Industry
For the Manufacturing - Apparel & Accessories industry and Consumer Cyclical sector, Ping An Biomedical Co's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Ping An Biomedical Co's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ping An Biomedical Co (PASW) has a Cash-to-Debt of 0.11 as of Sep. 2025. This is 1000% above median its historical median of 0.01. According to the industry distribution chart, Ping An Biomedical Co ranks #764 out of 1011 companies in the Manufacturing - Apparel & Accessories industry, placing it in the top 75.6%.
Is Ping An Biomedical Co's Cash-to-Debt too high?
Ping An Biomedical Co's current Cash-to-Debt of 0.11 is 1000% above median its 10-year median of 0.01. The Manufacturing - Apparel & Accessories industry median Cash-to-Debt is 0.46. Ping An Biomedical Co's value of 0.11 is 76.1% below this industry median. Based on the distribution chart, Ping An Biomedical Co ranks #764 out of 1011 companies in the Manufacturing - Apparel & Accessories industry, which is in the bottom quartile relative to peers. Overall, Ping An Biomedical Co has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Ping An Biomedical Co's Cash-to-Debt compare to DXYN and CULP?
According to the Manufacturing - Apparel & Accessories industry distribution chart, Ping An Biomedical Co ranks #764 out of 1011 companies for Cash-to-Debt. This places Ping An Biomedical Co in the lower half of its industry. The industry median Cash-to-Debt is 0.46. Ping An Biomedical Co's value of 0.11 is 76.1% below this benchmark. While the company's 10-year median is 0.01 vs. the industry median of 0.46, Ping An Biomedical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Manufacturing - Apparel & Accessories company?
The median Cash-to-Debt among Manufacturing - Apparel & Accessories companies is 0.46, based on 1,011 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ping An Biomedical Co's current Cash-to-Debt of 0.11 is 76.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Manufacturing - Apparel & Accessories industry, the median Cash-to-Debt is 0.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ping An Biomedical Co's current Cash-to-Debt is 0.11, which is 1000% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ping An Biomedical Co stock overvalued right now?
Ping An Biomedical Co (PASW) has a current Cash-to-Debt of 0.11. The current Cash-to-Debt is 0.11, which is 1000% above median its 10-year median of 0.01 and 76.1% below the Manufacturing - Apparel & Accessories industry median of 0.46. Ping An Biomedical Co's overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Ping An Biomedical Co (PASW), the current Cash-to-Debt is 0.11 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ping An Biomedical Co Ltd formerly Majestic Ideal Holdings Ltd is a Cayman Islands-based holding company, conducting operations through its PRC subsidiary, NewBrand. The group is a provider of SCM services in the apparel industry, offering solutions for a broad range of yarn products, textiles, and finished garments. Its service offerings encompass every key aspect of the supply chain of textile products, such as market trend analysis, product design and development, raw material sourcing, production and quality control, and logistics management. The group has two reportable segments, yarns and finished garments. The majority of its revenue is generated from the sale of yarns, including pure cashmere and cashmere-mix yarn, merino wool, cotton, and fancy yarn.
17GF Score
Get the complete analysis for PASW
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PASW has been successfully added to your 
